Mylan launches generic Paraplatin injection

PITTSBURGH — Mylan on Monday announced the launch of carboplatin injection, 50-mg/5-ml, in multi-dose vials. The drug is the generic version of Paraplatin injection from Bristol-Myers Squibb.



The company also received final approval for the carboplatin injection 150-mg/15-ml, 450-mg/45-ml and 600-mg/60-ml multi-dose vials, with plans to launch those strengths at a later date.



Carboplatin injection is used for the initial treatment of advanced ovarian carinoma in combination with other approved drugs. Carboplatin had sales in the United States of $30.4 million for the 12 months ended March 31, according to IMS Health.